Immuno-modulating drug under investigation in multiple sclerosis and moderate-to-severe Crohn's disease. European approval has been delayed due to concerns about animal data showing risk of cancer after long-term exposure and teratogenicity. Although in MS, laquinimod slows worsening of disability, its effect on relapses is modest.
Oral Initial dose ranging studies suggest 0.6mg/day for significant surrogate response in multiple sclerosis.
- Hepatic enzyme dearrangement reported
Cautions and Interactions
- ↑ Yang JS, Xu LY, Xiao BG, Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. Journal of neuroimmunology. 2004 Nov; 156(1-2):3-9.(Link to article – subscription may be required.)